Central Nervous System-related Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34657908/
doi: 10.2169/internalmedicine.6351-20. 1 Department of Hematology, Nippon Medical School, Japan. 2 Department of Diagnostic Pathology, Nippon Medical School Hospital, Japan. 3 Department of Integrated Diagnostic Pathology, Nippon Medical School, Japan....
XBP-1s Promotes B Cell Pathogenicity in Chronic GVHD by Restraining the Activity of Regulated IRE-1α-Dependent Decay - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34659198/
doi: 10.3389/fimmu.2021.705484. 1 Microbiology & Immunology, Medical University of South Carolina, Charleston, SC, United States. 2 Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research...
Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34631716/
Regulatory T cell (Treg) reconstitution is essential for reestablishing tolerance and maintaining homeostasis following stem-cell transplantation. We previously reported that bone marrow (BM) is highly enriched in autophagy-dependent Treg and...
-
GvHD Connect4yrKey Points • Conclusion/Relevance: “Using pDC-specific BDCA2-DTR mice in which diptheria toxin administration results in global pDC [plasmacytoid dendritic cells] depletion, we demonstrate that pDC depletion hampers BM [bone marrow], but not Show More
Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34614506/
Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. This phase...
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34628534/
The combination of hypomethylating agents and venetoclax has revolutionized the therapeutic landscape of acute myeloid leukemia (AML), especially for patients previously deemed unfit for curative-intent treatment. Some of these patients...